Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages

Invivyd, Inc. (NASDAQ:IVVD) has received an average recommendation of “Hold” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $8.00.

A number of research analysts have recently weighed in on IVVD shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of Invivyd in a report on Thursday, February 26th. Finally, D. Boral Capital reissued a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th.

Insider Activity at Invivyd

In other Invivyd news, insider Julie Green sold 20,964 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the transaction, the insider owned 107,717 shares in the company, valued at $170,192.86. This trade represents a 16.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Robert D. Allen III sold 19,392 shares of Invivyd stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total transaction of $30,639.36. Following the completion of the transaction, the insider owned 114,487 shares of the company’s stock, valued at $180,889.46. The trade was a 14.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 227,172 shares of company stock worth $354,534 in the last three months. Corporate insiders own 25.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Invivyd during the second quarter worth $27,000. GSA Capital Partners LLP grew its position in shares of Invivyd by 85.0% in the third quarter. GSA Capital Partners LLP now owns 805,221 shares of the company’s stock valued at $886,000 after purchasing an additional 369,891 shares in the last quarter. CIBC Asset Management Inc bought a new stake in shares of Invivyd during the 4th quarter valued at $37,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Invivyd during the 4th quarter valued at $36,000. Finally, DRW Securities LLC purchased a new stake in Invivyd during the 4th quarter worth about $27,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Stock Performance

NASDAQ IVVD opened at $1.80 on Friday. The company has a market capitalization of $508.68 million, a PE ratio of -3.83 and a beta of 0.61. Invivyd has a 52-week low of $0.46 and a 52-week high of $3.07. The company has a 50-day simple moving average of $1.99 and a 200 day simple moving average of $1.84.

Key Stories Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Q4 revenue and reported EPS surprised to the upside vs. some expectations — management reported $17.2M in revenue for Q4 and highlighted strong revenue growth in the release, which supports the stock move higher. Q4 Results & Business Highlights
• Positive Sentiment: Executive hire — Invivyd named Michael Mina, M.D., Ph.D., as Chief Medical Officer, a credentialed appointment that investors view as strengthening clinical and development leadership. CMO Appointment
• Positive Sentiment: Clinical program updates — the company provided DECLARATION trial updates and other development milestones in its release and slide deck, which investors typically reward when accompanied by clear timelines or progress. Clinical Updates
• Neutral Sentiment: Investor materials and transcripts posted — the company released an earnings slide deck and the earnings call transcript; these provide more detail but have produced mixed interpretations so far. Slide Deck
• Negative Sentiment: Company remains unprofitable with negative margins and return on equity — financial metrics show large negative net margin and negative ROE, underscoring ongoing profitability risk that can cap valuation. Market Performance & Metrics
• Negative Sentiment: Conflicting third‑party transcripts reported a small EPS miss, creating short‑term confusion/volatility among traders; monitor updated filings and the company release for the definitive figures. Third‑party Transcript

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.